Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
December 8, 2025BloodOpen Access

Safety and efficacy of CD19/CD22/CD20 multi-targeted CAR-T therapy in patients with refractory/relapsed B-cell non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

LKLiqing KangHGHongfei GuHZHongjia Zhu

Discussion

Loading...

Member takes

Overview

Open-label trial shows improved safety and efficacy in refractory B-cell non-Hodgkin lymphoma using multi-targeted CAR-T therapy, implying potential for broader applications.

Key Points

  • 75% overall response rate was achieved with the CD19/CD22/CD20 multi-targeted CAR-T therapy in heavily pretreated patients.
  • Patients exhibited a median age of 53 years, with all having highly refractory disease prior to treatment.
  • Assessment of safety included monitoring for cytokine release syndrome, with a significant portion experiencing this side effect.
  • Findings indicate that this therapy shows promise for patients previously failing multiple lines of treatment, necessitating further clinical trials.

Cite This Study

Kang et al. (2025) studied this question.

synapsesocial.com/papers/69362f694fa91c937236df41https://doi.org/10.1182/blood-2025-3713
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Updated clinical outcomes of a Phase I/II trial of bispecific CD19/CD20-targeted CAR-T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma2025
  2. 2CD19/CD22 bispecific CAR-t cell therapy for relapsed/refractory large b-cell lymphoma: A prospective, single-arm, single-center, phase 2 clinical trial2025 · 2 citations
  3. 3Sequential CD19/CD22 CAR-T cell therapy following ASCT shows improved efficacy versus CAR-t alone in relapsed/refractory large B-cell lymphoma2025
  4. 4Prospective phase I/II study of CD19-directed CAR-t therapy in relapsed/refractory central nervous system lymphoma: Clinical outcomes and safety profile2025 · 1 citations
  5. 5Sequential CD19 and CD22 CART for relapsed and refractory B cell ALL: Phase I results2025